Neogen First Quarter 2025 Earnings: EPS Misses Expectations

Simply Wall St

October 11, 2024

Neogen (NASDAQ:NEOG) First Quarter 2025 Results

Key Financial Results

Revenue: US$217.0m (down 5.3% from 1Q 2024).
Net loss: US$12.6m (down from US$1.50m profit in 1Q 2024).
US$0.06 loss per share (down from US$0.007 profit in 1Q 2024).

earnings-and-revenue-history — NasdaqGS:NEOG Earnings and Revenue History October 11th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Neogen EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 100%.

Looking ahead, revenue is forecast to grow 4.1% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 7.7% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Neogen's balance sheet.

If you're looking to trade Neogen, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Neogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.